• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy

    7/24/25 9:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $WINT alert in real time by email

    Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy

    Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB

    WARRINGTON, Pa., July 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced it has entered into a Common Stock Purchase Agreement for up to $500 million to establish an equity line of credit ("ELOC") and bolster its BNB cryptocurrency treasury strategy. The company also entered into an additional $20 million stock purchase agreement with Build and Build Corp. Ninety-nine percent of the proceeds from the ELOC and Build and Build Corp will be allocated to acquiring BNB cryptocurrency. The ELOC may not be used until the Company has obtained stockholder approval to increase its authorized shares of common stock.

    "We are excited to incorporate these new facilities to enable our future BNB acquisitions as part of our BNB treasury strategy," stated Jed Latkin, CEO of Windtree. "Pending stockholder approval, the opportunity to secure additional funds for purchasing more BNB cryptocurrency is essential to our strategy."

    Establishing the ELOC reflects Windtree's strategy to diversify its treasury assets and leverage the potential of blockchain-based digital currencies. The Company remains committed to prudent financial management while exploring innovative avenues to drive stockholder value.

    "Windtree's strategy to integrate BNB into its treasury reflects a forward-thinking approach to value creation," said Patrick Horsman, CFA, Director of Build and Build Corp. "The ELOC provides the flexibility and scale needed to execute on this digital asset treasury vision."

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Windtree Therapeutics, Inc.

    Windtree Therapeutics, Inc. is a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners.

    About Build and Build Corp

    Build and Build Corp is a dynamic company established by Patrick Horsman, Joshua Kruger, and Johnathan Pasch, who together bring over 43 years of expertise in hedge funds and digital asset management. The company is backed by prominent investors, including Discovery Capital, Off The Chain Capital, Kraken, Galaxy Digital, Gaia Digital Asset, and Silvermine, supporting its mission to deliver innovative solutions in the financial and digital asset sectors.

    Forward-Looking Statements

    The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: risks related to obtaining stockholder approval for the Build and Build Corp transaction and satisfying the other conditions necessary to consummate the transaction and related transactions, including the Company's abilities to meet the conditions required to make sales pursuant to the ELOC; the Company's ability to manage costs and execute on its operational and budget plans; risks related to the regulatory environment for cryptocurrency transactions; and the Company's ability to develop and maintain its BNB Crypto Treasury Strategy. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.

    Contact Information:

    Eric Curtis

    [email protected]



    Primary Logo

    Get the next $WINT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kelly Leanne

      3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      1/14/25 4:17:38 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      10/9/24 7:46:52 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Pelletier Saundra L

      3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      8/14/24 4:24:25 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Leadership Updates

    Live Leadership Updates

    See more
    • Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

      6/9/25 8:15:00 AM ET
      $ADTX
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

      WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors ("Board"). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. Ms. Kelly has served as GRI Bio's Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors w

      1/13/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Announces Leadership Transition Plan With Industry Veterans

      WARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board. Mr. Fraser has ser

      11/14/24 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      10/9/24 7:46:52 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fraser Craig bought $2,550 worth of shares (2,500 units at $1.02), increasing direct ownership by 5% to 57,877 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      9/28/23 7:24:59 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fraser Craig bought $2,250 worth of shares (2,500 units at $0.90), increasing direct ownership by 5% to 55,377 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      9/27/23 7:34:59 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Financials

    Live finance-specific insights

    See more
    • Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. "The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a revenue generating company by seeking to identify and acquire revenue-generating FDA-approved assets while advancing our cardiology and oncology pipeline," said Jed Latkin, Chief Executive

      5/16/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician

      4/15/25 8:00:00 AM ET
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evofem Reports Fourth Consecutive Year of Net Sales Growth

      -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

      3/24/25 8:30:00 AM ET
      $ADTX
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $WINT
    SEC Filings

    See more
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      7/24/25 9:05:12 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      7/17/25 9:24:36 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Windtree Therapeutics Inc.

      EFFECT - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      7/14/25 12:15:09 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy

      Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced it has entered into a Common Stock Purchase Agreement for up to $500 million to establish an equity line of credit ("ELOC") and bolster its BNB cryptocurrency treasury strategy. The company also entered into an additional $20 million stock purchase agreement with Build and Build Corp. Ninety-ni

      7/24/25 9:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services

      WARRINGTON, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is pleased to announce a strategic partnership with Kraken, a leading global cryptocurrency platform, to provide custody, trading, and over-the-counter (OTC) services for Windtree's BNB Crypto Treasury Strategy. The parties have signed a term sheet, to be memorialized in a definitive agreement following shareholder approval of Windtree's previously announced securities purchase agreement, with potential for up to an additional $140 million in future subscriptions, led by Build and Build Corp. This partnership positions Windtree to leverage Kraken's industry-leadi

      7/22/25 9:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions

      WARRINGTON, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is excited to announce it has entered into a $60 million securities purchase agreement led by Build and Build Corp, with the potential for up to an additional $140 million in gross proceeds in future subscriptions, for total subscriptions of up to $200 million. The proceeds, expected to be in the form of cash, shares of Osprey BNB Chain Trust and BNB, from this financing, upon closing, is to be primarily used to launch a BNB crypto treasury strategy and purchase BNB, positioning Windtree as a leader in the BNB digital asset . Subject to shareholder approval and the

      7/16/25 9:22:53 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

      Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/4/21 6:09:49 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

      SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 7:15:44 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Windtree Therapeutics Inc.

      SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 3:40:27 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

      SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 8:53:39 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care